Cancer Pain Market to Reach US$14.69 Billion by 2035, Driven by Rising Cancer Burden and Demand for Pain Management

The global cancer pain market was valued at USD 8.28 billion in 2025 and is expected to reach USD 14.69 billion by 2035, growing at a CAGR of 5.9% during the forecast period 2026-2035. The market is gaining momentum as the growing global burden of cancer, increasing prevalence of cancer-related pain, and rising demand for effective pain management therapies continue to support treatment adoption. Advances in opioid and non-opioid therapies, targeted pain management, and supportive cancer care are further contributing to market expansion.

The competitive opportunity is increasingly focused on effective pain control, improved treatment safety, targeted therapies, and personalized pain management approaches. Growing emphasis on improving quality of life for cancer patients is encouraging the development and adoption of therapies designed to provide sustained pain relief while addressing treatment-related challenges. The market is therefore shifting toward multimodal pain management, innovative therapeutics, personalized treatment strategies, and improved supportive care, supporting sustained growth in the global Cancer Pain Market through 2035.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/cancer-pain-market?sai-v

Recent Developments
August 2026: North America continued advancing cancer pain management through multidisciplinary oncology and palliative care models, while increasing attention was placed on personalized pain assessment and multimodal treatment approaches.

July 2026: Europe continued strengthening cancer pain research, with clinical development increasingly exploring alternatives and improvements to traditional opioid-centered treatment. Current research is emphasizing individualized analgesic selection and management of mixed nociceptive and neuropathic pain.

June 2026: Asia-Pacific continued expanding research into AI-enabled cancer pain management, including pain assessment, analgesic decision-making, remote monitoring, and interventional planning, supporting more personalized and longitudinal care.

May 2026: North America and Europe continued evaluating novel approaches for cancer pain, with clinical trials increasingly investigating dual-mechanism analgesics, novel drug-delivery systems, and non-opioid therapeutic targets. Opioid receptors still represented the largest therapeutic target category in the clinical-trial landscape.

April 2026: The global cancer pain market increasingly focused on multimodal pain management, AI-driven phenotyping, advanced drug-delivery technologies, and mechanism-based therapies. Research into micro/nano drug-delivery systems is also gaining attention for improving analgesic delivery while addressing limitations associated with conventional systemic treatments.

Key Players

CK Life Sciences (WEX Pharmaceuticals Inc.) | Mundipharma International | Orexo AB | Daiichi Sankyo Company, Limited | Hisamitsu Pharmaceutical Co., Inc. | Pfizer Inc. | Grünenthal | Teva Pharmaceutical Industries Ltd. | Galena Biopharma | Meda Pharmaceuticals | Vertex Pharmaceuticals Incorporated | Dogwood Therapeutics, Inc. | Others

Key Highlights
CK Life Sciences (WEX Pharmaceuticals Inc.) - Holds a 10.2% share, supported by its focus on cancer pain therapeutics and development of innovative pain-management solutions.

Mundipharma International - Holds a 9.8% share, driven by its established portfolio of pain-management medicines and strong expertise in opioid-based cancer pain treatment.

Orexo AB - Holds a 8.7% share, strengthened by its specialty pharmaceutical portfolio and focus on innovative drug-delivery and pain-management therapies.

Daiichi Sankyo Company, Limited - Holds a 8.4% share, supported by its broad pharmaceutical capabilities, oncology expertise, and development of therapies addressing cancer-related conditions.

Hisamitsu Pharmaceutical Co., Inc. - Holds a 7.9% share, driven by its extensive pain-relief portfolio, transdermal delivery technologies, and established pharmaceutical presence.

Pfizer Inc. - Holds a 7.6% share, supported by its extensive pharmaceutical portfolio, global distribution capabilities, and oncology and supportive-care expertise.

Grünenthal - Holds a 7.2% share, strengthened by its specialization in pain management and development of therapies for acute and chronic pain conditions.

Teva Pharmaceutical Industries Ltd. - Holds a 6.8% share, driven by its broad generic and specialty pharmaceutical portfolio, global manufacturing capabilities, and pain-management products.

Galena Biopharma - Holds a 5.4% share, supported by its oncology-focused development activities and therapeutic programs addressing cancer-related conditions.

Meda Pharmaceuticals - Holds a 4.9% share, driven by its specialty pharmaceutical portfolio and presence in pain-management and supportive-care treatments.

Vertex Pharmaceuticals Incorporated - Holds a 4.2% share, supported by its innovative approach to pain therapeutics and development of non-opioid treatment technologies.

Dogwood Therapeutics, Inc. - Holds a 3.5% share, strengthened by its focus on novel pain therapeutics and development of treatments targeting chronic and neuropathic pain.

Others - Hold a combined 25.4% share, comprising additional pharmaceutical and biotechnology companies involved in opioid, non-opioid, nerve-blocking, oncology supportive care, and emerging cancer pain therapies.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=cancer-pain-market?sai-v

Market Drivers
- Rising global cancer burden and increasing number of patients experiencing cancer-related pain, driving demand for effective pain-management therapies.

- Growing adoption of opioid and non-opioid analgesics for managing moderate to severe cancer pain across different stages of the disease.

- Increasing prevalence of advanced and metastatic cancers, where cancer-related pain and treatment-associated pain are more common.

- Growing awareness of comprehensive cancer pain management and increasing emphasis on improving patient comfort and quality of life.

- Rising adoption of multimodal pain-management approaches combining - pharmacological therapies, interventional procedures, and supportive care.

- Increasing healthcare expenditure and expanding access to oncology and palliative care services across developed and emerging markets.

- Growing investment in research and development of novel analgesics, targeted therapies, drug-delivery systems, and non-opioid alternatives for cancer pain management.

Industry Developments
- Development of novel non-opioid analgesics and targeted pain therapies aimed at addressing limitations associated with conventional opioid-based treatment.

- Increasing research into innovative drug-delivery systems, including extended-release, transdermal, injectable, and localized pain-management therapies.

- Strategic collaborations between pharmaceutical companies, biotechnology firms, oncology centers, and research institutions to advance cancer pain treatment.

- Growing clinical research into combination therapies designed to improve pain control while reducing adverse effects and treatment-related complications.

- Increasing adoption of personalized pain-management approaches based on cancer type, pain severity, patient characteristics, and treatment response.

- Expansion of palliative care and supportive oncology programs focused on improving pain control, functional outcomes, and quality of life for cancer patients.

Regional Insights
North America - 41% share: "Driven by the high cancer burden, advanced oncology and palliative care infrastructure, strong adoption of pain-management therapies, and significant pharmaceutical research activity."

Europe - 30% share: "Supported by established cancer-care systems, growing emphasis on palliative care, increasing awareness of cancer pain management, and widespread availability of analgesic therapies."

Asia Pacific - 23% share: "Fueled by the rising cancer burden, large patient population, improving healthcare infrastructure, increasing oncology expenditure, and expanding access to pain management treatments."

Latin America - 4% share: "Supported by increasing cancer incidence, improving access to oncology and palliative care services, and growing awareness of comprehensive cancer pain management."

Middle East & Africa - 2% share: "Driven by rising cancer prevalence, improving oncology infrastructure, increasing access to palliative care, and growing adoption of cancer pain-management therapies."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-pain-market?sai-v

Key Segments
➥ By Drug Class

Opioids: Represents the dominant segment, driven by their established role in managing moderate-to-severe cancer pain, widespread clinical use, and effectiveness in providing analgesic relief for advanced cancer patients.

NSAIDs: Represents a significant segment, supported by their use in managing mild-to-moderate cancer pain, inflammation, and pain associated with bone and tissue complications.

Morphine: Represents a major segment, fueled by its established position as a standard opioid analgesic for moderate-to-severe cancer pain and continued use in palliative and supportive cancer care.

Non-Opioids: Represents a significant segment, driven by increasing use for mild-to-moderate pain and as part of multimodal pain management approaches designed to reduce reliance on opioid therapy.

Nerve Blockers: Represents a growing segment, supported by their use in managing localized, neuropathic, and treatment-related cancer pain when conventional systemic analgesics provide inadequate relief.

Others: Represents an expanding segment, fueled by continued development and adoption of adjuvant analgesics and complementary pharmacological approaches for complex cancer pain management.

➥ By Application

Lung Cancer: Represents a significant segment, driven by the high burden of cancer-related pain associated with advanced disease, tumor progression, and treatment-related complications.

Colorectal Cancer: Represents an important segment, supported by the occurrence of pain associated with tumor progression, surgical interventions, and advanced colorectal disease.

Breast Cancer: Represents a major segment, fueled by the large patient population and the occurrence of cancer-related, treatment-related, and metastatic pain, particularly in advanced disease.

Prostate Cancer: Represents a significant segment, supported by the prevalence of bone metastases in advanced prostate cancer and the resulting need for effective pain management.

Blood Cancer: Represents an important segment, driven by pain associated with disease progression, bone involvement, treatment procedures, and complications associated with hematologic malignancies.

Others: Represents a growing segment, supported by the broad occurrence of pain across other cancer types and increasing demand for individualized pain management strategies.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by ease of administration, patient convenience, widespread availability of oral analgesic formulations, and suitability for long-term cancer pain management.

Parenteral: Represents a significant segment, supported by the need for rapid and controlled pain relief in hospitalized patients, advanced cancer cases, and patients unable to tolerate oral medications.

Others: Represents a growing segment, fueled by increasing use of alternative delivery routes and specialized approaches for patients requiring localized or non-oral pain management.

➥ By End-User

Hospitals: Represents the dominant segment, driven by the high number of cancer patients requiring comprehensive pain management, availability of specialized oncology services, and treatment of severe or complex cancer pain.

Homecare: Represents a rapidly growing segment, supported by the increasing shift toward home-based palliative care, patient preference for comfort-focused treatment, and the need for long-term cancer pain management outside hospital settings.

Specialty Clinics: Represents a significant segment, fueled by the expansion of specialized oncology and pain-management services and increasing demand for individualized treatment plans.

Others: Represents a growing segment, supported by the adoption of cancer pain management across palliative care centers, hospices, ambulatory facilities, and other specialized healthcare settings.

Explore Report Here: https://www.datamintelligence.com/research-report/cancer-pain-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.